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Abstract 
Parasitic nematode infections affect millions of people worldwide and are a significant cause of 
human and veterinary disease. Chronic infections cause debilitating health problems in humans, 
domestic animals, and livestock. Infections are treated using anthelmintic drugs, some target 
nicotinic acetylcholine receptors located in several different tissues. The exact mode of action of 
antinematode drugs is unknown. Research leading to better understand the mode of action is 
desirable to appreciate how resistance mechanisms develop. There is an urgent need for novel 
therapeutic agents to overcome resistance.  
 
This study considered Anycylstoma caninum ACR-16 as a drug target and was investigated using 
two-electrode voltage-clamp electrophysiology. This technique allowed us to explore several 
agonist and antagonists of ACR-16 and their pharmacology expressed in X. laevis oocytes. The 
sequence of Acn-ACR-16 was compared with Asu-ACR-16, another homomeric nicotinic 
acetylcholine receptor, but widely distributed in Ascaris tissue. Also, the concentration-current-
response relationships and the potencies of agonists are demonstrated for Acn-ACR-16. We 
concluded that Acn-ACR-16 was not sensitive to many of the currently used cholinomimetic 
anthelmintics. Though, the A. caninum channel was most sensitive to 3-bromocytisine unlike 
nicotine which was the most potent agonist for A. suum ACR-16 receptor. When considering 
antagonist pharmacology, the A. caninum receptor was moderately inhibited by α-BTX while Asu-
ACR-16 was almost insensitive. 
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Xle, Xenopus laevis; cRNA, complementary RNA; STH, soil transmitted helminths; SEM, standard 
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Introduction 
Parasitic nematodes can be gut or tissue dwelling, also known as soil transmitted helminths and 
filarial worms respectively. Infections caused by hookworms (mainly Necator americanus and 
Ancylostoma duodenale) are one of the leading neglected tropical disease, affecting approximately 
500 million people worldwide; especially in the developing regions of Asia, Africa, Latin America 
and the Caribbean (Pullan et al. 2014; Loukas et al. 2016; P. Hotez 2008). These infections account 
for >4 million disability adjusted life years (DALYs) lost annually and an estimated global 
economic loss of over US$100 billion (Loukas et al. 2016; Bartsch et al. 2016). The blood 
feeding nematodes do not directly account for substantial mortality; instead the major clinical 
manifestation of hookworm infection are the consequences of chronic intestinal blood loss.  Severe 
infection can result in poor iron deficiency, anemia, weight loss, abdominal pain, protein loss, and 
diarrhea (P. J. Hotez and Pritchard 1995; Bethony et al. 2006). Hookworm infections pose a major 
health threat to adolescent girls, women of reproductive age and children (Menzies et al. 2014; 
Brooker et al. 2008). Heavy worm burden can result in impaired physical and cognitive 
development in children and poor outcomes for pregnant women and their newborns (Guyatt et al. 
2000; P. J. Hotez et al. 2014; de Silva et al. 2003).  
 
Current hookworm control strategies are limited to deworming of infected people using 
anthelmintic drugs combined with ancillary strategies such as improvement of (Albonico et al. 
2003) water, sanitation and hygiene (WASH) in endemic regions (WHO 2015; Campbell et al. 
2018). At this time, there is no effective vaccine for human use in medical circulation (Hewitson 
and Maizels 2014; Diemert et al. 2008), with limited number of drug options. Unfortunately, 
failure of mass drug administration in prevention of hookworm transmission in endemic regions 
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due rapid reinfection rate, diminished efficacy or resistance of anthelmintic agents combined with 
the fact that adult hookworms can survive up to 7 years in the human gut producing thousands of 
ova per day complicates the issue (Albonico et al. 1995; Bennett and Guyatt 2000; Knopp et al. 
2012; Albonico et al. 2003). Due to all of these contributing factors, novel drug targets and drugs 
are required to for efficient of parasitic infections. 
Research has focused on several different parasitic ion channels because they are a major target 
binding site of most classes of antinematodal agents (Wolstenholme 2011). Ion channels are 
essential for fundamental physiological functioning in STHs. Nicotinic acetylcholine receptors 
(nAChRs) which belong to the cys-loop ligand gated ion channel family serve as synaptic 
transmission proteins and mediate fast transduction of signals by opening an intrinsic ion channel. 
They form pentameric channels which can be homomeric or heteromeric that compose a central 
pore. Nicotinic anthelmintics such as pyrantel, levamisole and oxantel selectively paralyze 
nematodes by activating cholinergic ion-channels (nAChRs) in their body wall musclulature 
(Williamson et al. 2009; Abongwa et al. 2017). The significance of nematode nAChRs as drug 
targets has been underlind by the recent development of novel amino-acetonitrile compounds 
(Kaminsky et al. 2008).  
 
Ancylostoma caninum is the most widespread and pathogenic hookworm of dogs (Nemzek et al. 
2015). Infestation typically results in anemia with bloody diarrhea, hemorrhagic enteritis, 
vomiting, anorexia, dehydration and poor weight gain, sometimes leading to death (Epe 2009; 
Dias et al. 2013). Zoonotic infection with A. caninum in humans has been associated with 
eosinophilic enteritis, localized myositis and cutaneous larva migrans (Prociv and Croese 1996; 
Bowman et al. 2010; Landmann and Prociv 2003; Traversa 2012). Amcylostoma caninum is most 
accessible of all hookworms and is closely related to human hookworm species, Ancylostoma 
duodenale and Necator americanus. Therefore, they are used as a model for human 
hookworm.(Nemzek et al. 2015; Prociv and Croese 1996; Blaxter 2000).  
In this study, a homologue ACR-16 was cloned and expressed from Ancylostoma caninum, clade 
V nematode parasite. The receptors were expressed in Xenopus laevis oocytes and we used two-
electrode voltage-clamp to understand the pharmacology. ACR-16 has been validated as a target 
in parasitic clade III roundworm, Ascaris suum by Abongwa et al. (2016). The focus of this study 
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was to generate a comparative pharmacological analysis of the homomeric channel and establish 
ACR-16 as a valid target in the hookworm parasites. 
 
Materials and Methods 
Ethical concerns 
No vertebrate animals were used directly in this study. Ancylostoma caninum larvae were a kind 
gift from Dr. Matt Brewer (Iowa State University, Ames, IA). Defolliculated Xenopus laevis 
oocytes were obtained from Ecocyte Bioscience (Austin, TX, USA).  
 
Sequence Analysis 
Database searches for A. caninum ACR-16 were performed with the BLAST search (WormBase 
Parasite), using the BLASTP algorithms (Altschul et al. 1997). Signal peptide predictions were 
done using the SignalP 4.1 server (Petersen et al. 2011), and membrane-spanning regions were 
identified using TMpred (Hofmann and Stoffel 1993). Alignment of the full-length amino acid 
sequences with Ascaris suum ACR-16 was carried out using Clustal Omega program (Sievers et al. 
2011). 
 
Cloning of Acn-ACR-16  
TRIzol ReagentTM (InvitrogenTM, Carlsbad, CA, USA) was used to extract total RNA from A. 
caninum larvae. cDNA was synthesized by using SuperScript VILO Master Mix ((InvitrogenTM, 
Carlsbad, CA, USA) according to the manufacturer’s instructions and served as a template for the 
amplification of multiple fragments of the Acn-ACR-16 sequence (WormBase Parasite Gene ID: 
ANCCAN_01899). We used Gibson assembly protocol to assemble the amplified fragments into 
the full length Acn-ACCR-16 sequence (Gibson et al. 2009). Full length product was subcloned 
into pTB207 expression vector by adding XhoI and ApaI restriction enzyme sites respectively to 
the forward primer (5’ end: TGGCGGCCGctcgagATGCGTTCGTTGGTCGTCTG) and reverse 
primers (3’ end: ATCAAGCTCgggcccTTAGGCGACGAGATATGGAGC) using In-Fusion 
cloning (Takara Bio USA, Inc.). The final cloned constructs were sequenced with pTB207 vector 
primers (forward, T7) and (reverse, SP6). Only positive clones were used for cRNA synthesis using 
in vitro transcription with the mMessage mMachine T7 transcription kit (Ambion) and the cRNA 
was aliquoted and stored at -80°C. 
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Oocyte Microinjection 
Defolliculted Xenopus laevis oocytes were injected with 25-50 ng of Acn-ACR‐16 cRNA either 
alone or in combination with 15-25 ng of each ancillary (A. suum ric-3, unc-50 and unc-74) in a 
total volume of 50 nL. Incubation solution consisting of 100mM NaCl, 2 mM KCl, 1.8 mM 
CaCl2.H2O, 1 mM MgCl2.6H2O, 5 mM HEPES, 2.5 mM pyruvate, 100 U•mL
-1 penicillin, and 100 
ug•mL-1 streptomycin (pH 7.5) was used to store Xenopus oocytes at ~19˚C for approximately 3 
hours prior to injections. The oocytes were injected at the animal pole using a nanoject II 
microinjector (Drummond Scientific, Broomall, PA, USA) and then transferred into a 96-well 
culture plate. In each well, 200 µL of incubation solution was placed with one oocyte and and the 
solution was changed daily. The oocytes were incubated at 19°C for for 2-7 days. This time period 
allowed for robust receptor expression.  
 
Two-Electrode Voltage Clamp Electrophysiology in Xenopus Oocytes 
Two-electrode voltage clamp electrophysiology recordings from Acn-ACR-16 expressed were 
performed as described by Abongwa et al. (2016) . BAPTA-AM, a calcium chelator, was added 
~3 hours prior to recordings to prevent endogenous calcium channel activated chloride channels. 
Non-injected oocytes served as negative control during recordings. The recordings were made 
using Axoclamp 2B amplifier (Warner Instruments, Hamdem, CT, USA) with oocyte clamped at 
-60 mV and Data were collected using Clampex 10.2 (Molecular devices, Sunnyvale, CA, USA). 
Microelectrodes were used for impaling oocytes were used via Flaming Brown horizontal 
electrode puller (Model P-97, Sutter Instruments Co., USA) and filled with 3 M KCl. The 
microelectrodes tips were carefully broken with a tissue paper to achieve a resistance of 2-5 MΩ 
in recording solution (100 mM NaCl, 2.5 mM KCl, 1 mM CaCl2·2H2O and 5 mM HEPES, pH 
7.3) in order to allow passage of large currents for maintaining adequate voltage clamp. 
 
Drug applications 
All drugs applied, except tribendimidine and derquantel, were purchased from Sigma Aldrich (St 
Louis, MO, USA). The drugs were solubilized in recording solution or DMSO (final working 
concentration did not exceed 0.1%). Derquantel and tribendimidine were a generous gift from 




Agonists of interest were used at a final concentration of 100 µM except tribendimidine (30 µM) 
due to solubility issues. In all experiments, 100 µM acetylcholine was applied first and all the 
responses were normalized to this control response. Each agonist was applied for 10s followed by 
3 minutes perfusion with recording solution. The sequence for application of agonists for 
determining the potency series was random and not predetermined. The concertation-response 
studies were conducted by application of the drug in ascending order of concentrations in order to 
minimize the desensitization by high concentrations of agonists. In each experiment the drug was 
applied for 10s followed by 3 minutes wash off with recording solution.  
 
All the antagonists in our study were used at a final concentration of 10 µM. For generating rank 
order potency series for the antagonists, a control application of 100 μM ACh was first initially 
followed by 3 minutes wash off. Thereafter, 100 μM acetylcholine was applied for 10 s, 
immediately followed by 10 s application of the antagonist in the continued presence of 100 μM 
ACh and then a final 10 s application of 100 μM ACh. At least 3 min drug wash off interval was 
allowed between applications in order to minimize desensitization. Note that, due to short time of 
drug application in this protocol, it is possible to underestimate the potency of an antagonist.  
 
Data and Statistical Analysis
Clampfit 10.3 (Molecular Devices, Sunnyvale, CA, USA) and GraphPad Prism 7.0 (Graphpad 
Software Inc., La Jolla, CA, USA) were used to analyze data. The peak currents in response to the 
applied agonists were measured and normalized to control current (100 µM acetylcholine). All 
completed drug application sequences on the oocytes were used for analysis without exclusion. If 
the recording became unstable, indicated by a change in the baseline holding current, all of that 
recording was rejected for analysis. The results expressed as mean ± SEM. The Hill equation was 
used to analyze the dose-response relationships by fitting log dose-response data points as 
described in (Boulin et al. 2008). Desensitization kinetics in response to the agonists were fitted 
using a single exponential decay fit: 
𝑓(𝑡) = ∑ 𝐴𝑖𝑒





where 𝑛 is the number of components, 𝐴 is the amplitude, 𝑡 is time, 𝜏 is the time constant, and 𝐶 is 
the constant y-offset for each 𝑖 component. The mean % inhibition produced by the antagonists on 
currents elicited by 100 μM acetylcholine were calculated using the equation: 
 




 × 𝐼𝑚𝑎𝑥  
)  100% 
 
where 𝐼𝑚𝑎𝑥 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 is the peak current of the control 30 s application of 100 μM ACh, 𝐼𝑚𝑎𝑥 is 
the peak current of the 100 μM ACh that preceded the 10 s co-application of ACh and antagonist. 
𝐼𝑎𝑛𝑡 is the minimal current during the co-application of 100 μM ACh and the antagonist. 𝐼𝑎𝑛𝑡 
𝑐𝑜𝑛𝑡𝑟𝑜𝑙 is the current at the same point from the beginning of the 30 s application as 𝐼𝑎𝑛𝑡 during 
the control 30 s application of 100 μM ACh. Statistical analyses were performed using t-test and 




Sequence comparison of Acn-ACR-16 with Asu-ACR-16  
We were able to identify the potential complete coding sequence of the homolog of ACR-16 in the 
dog parasite (Gene ID: ANCCAN_01899) by using the Asu-ACR-16 protein sequence (GeneBank: 
KP756901) as a query in a BLASTP search in the nematode protein database, WormBase Parasite.  
Acn-ACR-16 has all the structural characteristics of a nicotinic acetylcholine receptor subunit : a 
large extracellular NH2-terminal domain of ~200 amino acids involved in correct nAChR assembly, 
Cys-loop motif separated by 13 intervening amino acids, four transmembrane (TM) domains that 
forms the ion-conducting pore, a cytoplasmic domain inserted between TM3 and TM4 that helps 
in modulation of channel activity & ion conductance, six loops (A-F) and most importantly presence 
of vicinal cysteines (Y-x-C-C motif) in the C-loop making an alpha subunit. Figure 1 shows the 
protein sequence alignment of Acn-ACR-16 with Asu-ACR-16. Both the worms belong to different 
clade of nematodes, but their amino acid residues were highly conserved with an identity of 77.8% 
identity. There is lack of conservation in Acn-ACR-16 loops E and F which encouraged us to 




Acn-ACR-16 forms 3-bromocytisine sensitive nAChR 
We tested a selection of nicotinic agonists and cholinergic anthelmintics on the expressed A. 
caninum ACR-16 ligand gated ion channel. Figure 2A shows the rank order potency series for the 
agonists along with the representative traces. 3-Bromocytisine was the most potent agonist were 
the most potent (>130% of the acetylcholine current). Epibatidine, cytisine, nicotine and DMPP 
activated the receptor. Interestingly levamisole, oxantel, pyrantel, morantel, bephenium, and 
tribendimidine were not active on the expressed nAChR. The rank order potency series on Acn- 
ACR-16 when normalized to the control 100 µM acetylcholine current is: 3-bromocytisine > ACh 
>  epibatidine > cytisine > nicotine > DMPP >> levamisole = oxantel = pyrantel = morantel = 
choline = bephenium = tribendimidine. None of cholinomimetic anthelmintics currently used in the 
field activated the homomeric receptor which shows that this channel is distinct from the other 
somatic nAChRs of the nematodes.  
 
Comparative pharmacology of acetylcholine and 3-bromocytisine  
The concentration-response relationship was examined by application of drugs in ascending order 
(0.3-300 µM depending on the agonist). Figure 2B shows the representative recordings and 
concentration response curve induced by the application of acetylcholine and 3-BC. The initial 
application of 100 µM acetylcholine was used as an internal standard for normalization for each 
recording. The sigmoidal concentration-response fit gave an EC50 = 49.7 ± 3.3 μM for 
acetylcholine. 3-Bromocytisine produced a considerable left shift in the dose-response curve and 
gave a significantly lower EC50 = 1.5 ± 0.4 μM for 3-BC.  The curves for both the nicotinic agonists 
were steep but the hillslope (nH) values were not different significantly (nH = 2.5 ± 0.3 for ACh and 
2.4 ± 0.7 for 3-BC). The steep dose-response curves and the higher hill slope values (>1) suggests 
that the ligands are binding to more than one site in the receptor and exhibits positive cooperativity 
as expected of a homomeric ion channel. 
 
Acn-ACR-16 desensitization 
Desensitization defined as decrease or loss of biological response following prolonged or repetitive 
stimulation, is a common feature of the nAChRs including -7 homomeric nAChRs (Giniatullin et 
al. 2005; Picciotto et al. 2008; Quick and Lester 2002). In case of Ascaris suum ACR-16, all the 
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potent agonists exhibited desensitization (Abongwa et al. 2016). We observed similar trend 
characterized by the peak and waning current responses observed during maintained (for 10 s) 
agonist applications in case of Acn-ACR-16. Bar graph in figure 2C shows the time constants for 
desensitization observed with agonists. The time constant for desensitization was highest for 
epibatidine and lowest for 3-bromocytisine. The mean time constants for desensitization rates 
ranged between 1.5 and 4.8 s for of Acn-ACR-16 and were less than the rates observed in Asu-
ACR-16 (Abongwa et al. 2016).  
 
Ancillary factor ric-3 is required for functional expression of Acn-ACR-16  
For the heterologous expression of the Acn-ACR-16, we expressed the subunit protein cRNA with 
different ancillary proteins. Figure 3 shows the effects of co-injecting different ancillary proteins 
(ric-3, unc-50 and unc-74 from A. suum and ric-3 from X. laevis) in combination with ACR-16 
cRNA. None of the combinations, except Acn-ACR-16 with Asu-ric-3, gave robust responses to 
control 100 μM ACh.  In order to optimize the expressed we varied the amount of cRNA of Acn-
ACR-16 (25-50 ng) and Asu-ric-3 (15-25 ng). We measure the largest response from oocytes 




Six nAChR antagonists (10 µM each) were tested on the expressed cation selective homomeric ion 
channel. The antagonists were d-tubocurarine (dTC), mecamylamine, dihydro-β-erythroidine 
(DHβE), derquantel , hexamethonium, and α-bungarotoxin (α-BTX). We measured the mean % 
inhibition of the control 100 µM ACh current to determine the rank order potency of the antagonists. 
αBTX produced least inhibition of the acetylcholine mediated current while d-TC and mec were 
most potent (~100% inhibition of the control current). DhβE, a selective antagonist for α4β2 
receptors (Levin 2002), interestingly produced almost complete inhibition of acetylcholine currents. 
The complete rank order potency for antagonists (Figure 4) was: dTC ≈ mecamylamine ≈ DHβE > 





Comparison of pharmacology of Acn-ACR-16 with Asu-ACR-16 
In this study we have shown that ACR-16 from Ancylostoma caninum, the dog hookworm, 
expresses as a homomeric channel in Xenopus oocytes. Abongwa et al. (2016) successfully 
recapitulated and validated ACR-16 homolog from the pig parasite, Ascaris suum. Similar to A. 
suum channel, the Acn-ACR-16 was not sensitive to many of the currently used cholinomimetic 
anthelmintics including levamisole, pyrantel and tribendimidine. However, A. caninum 
homomeric cys-loop channel was most sensitive to 3-bromocytisine while nicotine was the most 
potent agonist for A. suum ACR-16 receptor. The concentration response curves for acetylcholine 
was slightly steeper for Asu-ACR-16 (nH = 3.9 ± 0.3) in comparison to Acn-ACR-16 (2.5 ± 0.3); 
which may account for higher sensitivity of acetylcholine for the pig nematode alpha nAChR (Asu-
ACR-16’s EC50 = 4.5 ± 0.2 μM; Acn-ACR-16’s EC50 = 49.7 ± 3.3 μM). In terms of antagonist 
pharmacology, the A. caninum cation channel was moderately inhibited by α-BTX (mean % 
inhibition = 49.3 ± 5. 2) while Asu-ACR-16 was nearly insensitive (mean % inhibition = 5.5 ± 
0.8).  In addition, DhβE produced complete inhibition of acetylcholine mediated responses on the 
Acn-ACR-16’s while A. suum homolog was moderately inhibited. In agreement with Abongwa et 
al. (2016), Acn-ACR-16 was highly sensitive to mecamylamine & d-TC and moderately sensitive 
derquantel & hexamethonium. The protein sequence of the ACR-16 homologues from both the 
nematode parasites is highly identical (77.8 % identity). But there are variable amino acids residues 
in the loops E and F which can account for  differences in the pharmacological properties 
(Corringer et al. 2000).  
 
Consideration of Acn-ACR-16 as a drug target 
Hookworms infections affects approximately 500 million people with 5.1 billion at risk for 
acquiring infection worldwide (Global Burden of Disease Study 2015; Pullan and Brooker 2012). 
Despite decades of strong research efforts and identification of promising candidate antigens, there 
are still no commercially available vaccines for human hookworm infections. Consequently, 
identification of novel drug targets is a practical and feasible approach to control these infections. 
In parasitic nematodes nicotinic acetylcholine receptors are required for various physiological 
functions. These ligand-gated ion channels are targets of important cholinergic antinematodal 
drugs such as levamisole & pyrantel and recently introduced “novel” anthelmintics including 
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tribendimidine & derquantel. ACR-16 has been shown to be an important for regulation of fast 
neurotransmission in C. elegans (Richmond and Jorgensen 1999). Asu-ACR-16 has been validated 
as a drug target in the pig parasitic nematode (Abongwa et al. 2016). We have successfully 
reconstituted a fully functional homomeric nAChR, ACR-16, in the Xenopus oocyte expression 
system from A. caninum, which is used as a model for human hookworm infections. The 
pharmacology of the receptor is distinct from the levamisole sensitive nematode receptors. The 
ACR-16 homologue also displayed some pharmacological differences from Asu-ACR-16. 
Benzimidazoles are the commonly used antiparasitic drugs for treatment of hookworm infections 
but there have been multiple reports of resistance in veterinary medicine and decreased cure rates 
in humans (Geerts and Gryseels 2000; De Clercq et al. 1997; Keiser and Utzinger 2008; Conder 
and Campbell 1995). There is a need for new drug target and ACR-16 may be a valid target site 
with the potential to circumvent resistance.  
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Figure 2A. The effects of nAChR agonists and antiparasitic drugs on Acn-ACR-16. 
Rank order potency series for nAChR agonists and anthelminitcs along with sample 
traces and mean ± SEM (n ≥ 4) is shown. Nicotine (nic), cytisine (cyt), 3-
bromocytisine (3-bc), epibatidine (epi), DMPP, choline (cho) are measured agonists. 
Levamisole (lev), oxantel (oxan), pyrant (pyr), morantel (mor), choline (cho), 
bephenium (beph), and tribendimidine (tbd) 
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Figure 2B. 3-Bromocytisine and ACh 
concentration-response relationship 
for Ancylostoma caninum ACR-16 in 
the absence of antagonists with 
associated traces. ACh and 3-bc dose-
response curves for Acn-ACR-16. 
For ACh the EC
50
 values were (mean 
± SEM) 49.7 ± 3.7 and the Hill slope 
(n
H
) = 2.5 ±. 0.3. For 3-bc the EC
50
 
values were (mean ± SEM) 1.5 ± 0.35 
and the Hill slope (n
H
) = 2.5 ± 0.1. 
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Figure 2C. Ancylostoma caninum 
ACR-16 desensitization rate constant 
fit. Desensitization responses to 
nicotine (nic), cytisine (cyt), 3-
bromocytisine (3-bc), epibatidine 
(epi), and acetylcholine (Ach) of Acn-
ACh-16 are represented via bar chart 
(mean ± SEM). The rank order for 
Acn-ACR-16 desensitization time 
constants is the following: 100 µM epi 
> 100 µM nic > 100 µM cyt > 100 µM 
ACh > 100 µM 3-bc. The 
desensitization rates ranged from 
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